Download presentation
Presentation is loading. Please wait.
Published byAmber Paul Modified over 8 years ago
1
CORRELATION BETWEEN HIV-1 MOLECULAR CHARACTERISTICS AND RESPONSE TO HAART IN PEDIATRIC POPULATION FROM SAO PAULO, BRAZIL Cristina Mendes de Oliveira, Rosangela Rodrigues, Carla M P Vazquez, Maria do Socorro Carneiro Ferrão, Alexandre Campeas, Márcia Crozatti, Silvia Marques, Luis Fernando de Macedo Brígido. Laboratório de Retrovírus, Instituto Adolfo Lutz, São Paulo, Brasil Instituto de Infectologia Emílio Ribas, são Paulo, Brasil
2
Decision on when to start ARV therapy is a matter of controversy even for adults Children pose additional challenges even in virological failure due to specific issues, including: –Potential interference with normal growth and development –Toxicity; Pharmaco-dynamics –Limited ARV options; posology limitations –Adherence
3
What is the contribution of molecular information to the management of children living with HIV/AIDS ARV drug resistance test were the fist molecular characterization brought into clinical practice routine, subsidizing salvage ARV therapy. Additional molecular characteristics of HIV-1 that provide surrogate markers do determine when and how to treat HIV infected children can be useful in subsidizing decision on starting as well as changing ARV therapy.
4
Methodology Inclusion criteriaInclusion criteria Informed consent from parents or gardian and additional informal consent for older children at inclusion visit Informed consent from parents or gardian and additional informal consent for older children at inclusion visit Naïve : samples collected before initiation of ARV (2001-2006) Treated : children or adolescent using EFV or LPV based HAART ( collected from 6 / 2005 to 11 / 2006 ) Viral load bDNA (Bayer); TCD4 ( BD), performed at certified National Network Laboratory HIV sequencing performed at Retrovirus Laboratory, Adolfo Lutz Institute
5
Samples collected at baseline EDTA blood collected at service and processed within 6 hs Cell lysade and plasma maintained at -70 °C Extraction plasma RNA and/or Cell DNA (Qiagem/GFX) RNA retrotranscrition (Superscript II, Invitrogen, USA) Nested PCR Sequencing (ABI 3100) with Big Dye chemistry (ABI,USA) Edition : Sequencher (Gene codes corp.,USA) Phylogeny : REGA, NCBI, SIMPLOT, PAUP Drug Resistance Mutations (DRM), Stanford HIV Database
7
Baseline Characteristics Naïve Treated n=16 n=79 Age (mean years ) 3.6 9.4 Gender (% males) 44% 54% Mean number of ARV regimens 0 5.7 TCD4 ( cels/mm 3 ) 1108 650 Plasma Viremia (log) 4.91 4.08 % undetectable 0% 24%
8
Clinical outcome of ARV treated cases 78 cases with follow up information 79.5% Asymptomatic 7% Bacterial Pneumonia 4% TB Other complications One death (adenocarcinoma) One loss to follow up (change town) - Citopenias in 6% - Pancreatitis - CMV
9
Outcome categories defined based on : (i)Viral load at last observation (end 2007- first semester of 2008) (ii)Clinical observation (patients’ pediatrician) at last documented visit and TCD4 cell counts (cells / mm3) at last observation GOOD RESPONDERS TCD4 counts over 350 and clinically asymptomatic POOR RESPONDERS TCD4 counts under 350 or clinical Aids related condition
10
Viral Load and TCD4 outcome TCD4 mean 650 cels/mm3 TCD4 mean 691cels/mm3 61% with TCD4 over 500 27% 200 - 500 12% below 200 24% aviremic - among viremic Log 10 4.54 35% aviremic - among viremic Log 10 3.91 At baseline At last visit
11
Treatment at last evaluation NNRTIs + EFV and/or LPV based HAART ARVAvir GR LPV 65%41%62% EFV 21%23%67% EFV+LPV 12%40%80%
12
Age (mean) % males number regimens (mean) Time on ARV (weeks) Time of follow up (weeks) % avir at baseline * Baseline Viremia among viremic Avir (<50c/ML) 8.7483.1395106524.62 Vir 2-4 Log 10 9.5423.4445105174.13 Vir> 4 Log 10 9.9574.250610454.71 Baseline characteristics by Virological outcome * P< 0.002
13
Presence of DRMs by virological strata TAM NRTI. DRM NNRTI DRM PI. DRM PI. sec/acc PI Major DRM Vir>4.03.135.041.226.1351.13 vir2-42.753.851.193.252.630.63 Avir2.683.941.252.822.470.35 Vir>4 x Avir P= 0.43 p=0.14 p=0.9 P<0.001 p<0.05 p<0.01 Mean number of DRM at RT and PT DRM Drug Resistance Mutations RT reverse transcriptase gene PT –Protease gene Tam -Tymidine Analogue mutations NRTI -Nucleoside analogue ARV class NNRTI - Non analogue ARV class PI -Protease inhibitor class Sec/acc -Secondary/accessory mutations Major- Principal mutations to PI
14
Proportion of DRM to NRTI class in ARV resistance codons at Reverse transcriptase (RT) by treatment outcome PR poor response; GR good response
15
Proportion of DRM to NNRTI class in ARV resistance codons at Reverse transcriptase (RT) by treatment outcome PR poor response; GR good response
16
Proportion of DRM to Protease Inhibitors (PI) at ARV resistance codon at PROTEASE by treatment outcome
17
Proportion of DRM to Protease Inhibitors (PI) at ARV resistance codon at PROTEASE by treatment outcome PR poor response; GR good response
18
Proportion of DRM to Protease Inhibitors (PI) at ARV resistance codon at PROTEASE by clinical outcome
19
Impact of DRM on treatment outcome V82A/F/T/SL90M GR 9% PR 45% 30% Proportion of selected major DRM at PR p<0.0052 P=0.067
20
Impact of DRM on treatment outcome Among cases currently using LPV based HAART P<0.0082 p=0.2 NNRTINRTI ALL NRTI TAM IP Acc /sec IP major GR1.64.83.12.50.25 PR1.34.33.34.80.90 GR Good responders ; PR Poor responders Mean number of DRM at RT and PT BY outcome
21
Impact of DRM on treatment outcome among cases using EFV based HAART NNRTINRTI ALL NRTI TAM IP Acc /sec IP major GR1.5430.75 0 PR0.34.673 0.3 Mean number of DRM at RT and PT GR Good responders ; PR Poor responders
22
Protease polimorphisms by pol clade
23
V3 loop signatures among naïve and treated cases stratified by poor responders (PR) and good responders (GR)
24
PR GR
25
Recombination patterns at gag (903-1920), pol (2252-3251) and env (7077-7609), positions related to HXB2 ( K03455). HIV-1 B HVI-1 F HIV-1 C BF mosaics
26
HIV-1 clades by virological outcome and clinical outcome
27
Predicted HIV tropism by virological and clinical outcome
28
V3 loop AA alignment of paired cell and plasma
29
Impact V3 mixtures on treatment outcome Proportion of V3 with mixtures Proportion of nu Mixtures N GR49%5.6739 PR44%2.4918 Mean number of Mixtures at V3 by outcome Most sequences ( 51% among GR and 54% among PR) do not show mixtures at V3 P<0.031
30
DIVERSIDADE - DIVERGENCIA intra- hospedeiro Arts et al. 2007
31
Conclusions Albeit treated for over a mean of 449 weeks (8.6 years) over one third of these children had viral load< 50 c/ml at last evaluation Protease inhibitors mutations, both major as well as accessory/ Secondary DRM, correlated to viremia and poor clinical outcome; some polymorphisms common among naïve cases and may have an impact in resistance evolution Presence of mixtures at V3 codons were associated to good clinical outcome
Similar presentations
© 2024 SlidePlayer.com Inc.
All rights reserved.